Submitted:
22 July 2026
Posted:
23 July 2026
You are already at the latest version
Abstract

Keywords:
1. Introduction
1.1. A Kill Law with No Internal State
1.2. What the Field Already Has, and What It Lacks
1.3. What This Paper Adds
2. The Coupled Multi-Timescale Model
2.1. State and Timescales
2.2. The Kill Kernel and the Linear–Quadratic Limit
2.3. Couplings, and Why the Back-Arm Is Load-Bearing
| Coupling | Model term | Biological basis | Key references |
|---|---|---|---|
| S → B (write; keystone) | k = κs | stress signalling drives the persistent transition; transcriptional write-and-inherit step | Li 2026; Gu 2022; Mothersill & Seymour 2001 |
| B → kill (tolerance back-arm) | r in r h | persister state lowers radiosensitivity to a subsequent dose; multiplicative and dose-dependent in fractionation data | Zhao 2023; Van den Berg 2020; Sharma 2010 |
| B → E (reseeding) | νρ(a)Np | persister reservoir buds near-parental progeny that repopulate; reversion | Zhao 2023; Ling 2026 |
| A gates B escape | ρ(a) | interferon / budding toggle releases progeny; bistable | Zhao 2023 |
| M → kill / write | α(x); −χḊ | oxygenation sets sensitivity; radiolytic depletion is the FLASH channel; reactive-oxygen handling couples M to B | Pratx & Kapp 2019; Forissier 2025; Russo 2024 |
| M → S (proposed) | redox priming | a redox excursion primes the write | Di Dio 2025 (proposed) |
2.4. The Reduction Tower
| Symbol | Meaning | Value / range used |
|---|---|---|
| α, β | LQ linear (lethal) and quadratic (sublethal) coefficients | 0.30 Gy⁻¹, 0.03 Gy⁻² illustrative; 0.127, 0.087 fitted (§6.5) |
| D, Ḋ | cumulative dose; dose rate | 8 Gy course; 60 Gy / 30 fx (clinical); scanned |
| h(t) | instantaneous kill hazard, Eq. 1 | Derived |
| Ns, Np | sensitive and persister surviving fractions | state; N(0) = (1, 0) |
| R | tolerance ratio (persister / sensitive hazard) | 0 ≤ r < 1; 0.5 illustrative, scanned; 0.063 fitted (§6.5) |
| g(h) | persister hazard functional | rh (mult.); additive; saturating (Figure 3) |
| k(t) | sensitive → persister write rate, Eq. 3 | Derived |
| s(t) | write signal (low-pass of hazard) | Derived |
| τw | write lag (consolidation time) | 0.15 course units; scanned |
| γ, κ | signal gain; write coupling strength | 1.0; 0.3 illustrative; κ = 0.086 fitted (§6.5) |
| H(t), K(t) | cumulative hazard ∫h; cumulative write ∫k | Derived |
| S(T) | total surviving fraction, Eq. 4 | — |
| T | end of treatment course | 1 (normalised) |
| Ω, Ω2, J | Magnus operator; 2nd-order term; commutator integral, Eq. 9 | — |
| L | per-fraction log-kill, αd + βd² (Corollary 2) | Derived |
| A, B, C | per-fraction factors e⁻ᴸ, e⁻ʳᴸ, e⁻ᵏᴸ (Corollary 2) | Derived |
| nw, M | consolidation delay in fractions; fractions with write active | 1.75 fx fitted, 95% interval [1.25, 2.50] ≈ 2.5 d at 5 fx/wk (§6.5) |
3. The Exact Survival Law and Its Scheduling Nulls
3.1. Axioms
3.2. Lemma 1 (LQ Recovery)
3.3. Theorem: The Closed-Form Surviving Fraction and Its History-Free Loci

3.4. Corollary 1: Write Generality and the Autonomy Boundary
3.5. Corollary 2: Fractionated Delivery Under a Delayed Write
3.6. The Order Effect Between the Loci: Exact and Approximate Components
3.6. What the Theorem Does Not Give


4. The Fractionation Specialisation Against Data
4.1. The Observations, and the Treatment of Radiosensitivity
4.2. Fit and Model Comparison
| Regime | LQAR | Model M |
|---|---|---|
| (i) Both free — RMS in log₁₀ | 0.184 | 0.159 |
| (i) Akaike / Bayesian criterion | −226.3 / −221.9 | −240.3 / −229.2 |
| (i) Fitted α (measured 0.116 Gy⁻¹) | 0.220 (+89%) | 0.127 (+9%) |
| (i) Fitted α/β (measured 2.32 Gy) | 4.35 (+88%) | 1.45 (−37%) |
| (ii) Both held to measured α, β — RMS | 0.769 | 0.279 |
| (ii) Overprediction of observed survival | 8.7–20.9× | — |
| (iii) Held-out fraction sizes — RMS | 0.198 | 0.211 |
| Fitted persister parameters | — | nw = 1.75 fx [1.25, 2.50]; κ = 0.086; r = 0.063 |

4.3. What the Fit Establishes, and What It Does Not

| Axioms # | Claim | Evidence / basis | Status |
|---|---|---|---|
| Axiom 1 | two differentially-killed compartments | Gu 2022; Zhao 2023; Forissier 2025 | Settled |
| Axiom 2 | one-way write; reversion frozen on course scale | Zhao 2023 (slow reversion); van den Berg 2020 (full reversal after recovery, radiation-direct) | Anchored: reversion real but slow vs course |
| Axiom 3 | multiplicative tolerance g=rh | Form untested in radiation: van den Berg 2020 fit an additive floor in survival, not a hazard modifier, and compare no forms | Assumption (sets the sign; see §4.2) |
| Axiom 4 | lagged write, τw > 0 | Li 2026 (adaptation scored at ≈1 wk; low-dose exposure confers resistance to a later high dose); van den Berg 2020 (phenotype over ≈2–3 wk); §6.5 (1.75 fx from radiation data) | Anchored; estimates differ in magnitude, agree that τw exceeds a fraction and is shorter than a course |
5. Framework Results Beyond the Core
5.1. The Consolidation-Timing Window
5.2. Bistable, Hysteretic Escape

5.3. The Selection Rule Across Layers
5.4. Non-Redundancy of the Couplings
6. Delivery Modalities Under One Account
7. Discussion
7.1. The Framework and the Theorem
7.2. What the Figures Establish, and What They Do Not
7.3. Repair and Redistribution, Externalised by Design
7.4. The Planning Quantities Become History-Dependent
7.5. What the State Might Represent
7.6. Predictions
7.7. Status, Limitations, and the Clinical Path
8. Conclusion
References
- Abbott, K., Hardo, G., Li, R., Bradley, J., Zarkan, A., & Bakshi, S. (2026). Stress History Establishes a Transient Tolerant State That Shapes Antibiotic Survival Upon Resuscitation. Advanced Science, e21993. [CrossRef]
- Ahmed, K. A., Correa, C. R., Dilling, T. J., et al. (2014). Altered fractionation schedules in radiation treatment: A review. Seminars in Oncology, 41(6), 730–750. [CrossRef]
- Alfonso, J. C. L., & Berk, L. (2019). Modeling the effect of intratumoral heterogeneity of radiosensitivity on tumor response over the course of fractionated radiation therapy. Radiation Oncology, 14, 88. [CrossRef]
- Almquist, K. J., & Banks, H. T. (1976). A theoretical and computational method for determining optimal treatment schedules in fractionated radiation therapy. Mathematical Biosciences, 29(1–2), 159–179. [CrossRef]
- Ayati, B. P., Kapitanov, G. I., & Loew, L. M. (2016). A mathematical modeling framework for the combined effects of radiotherapy and chemotherapy. arXiv:1603.00349.
- Belli, M., & Tabocchini, M. A. (2020). Ionizing radiation-induced epigenetic modifications and their relevance to radiation protection. International Journal of Molecular Sciences, 21(17), 5993. [CrossRef]
- Bergonié, J., & Tribondeau, L. (1906). Interprétation de quelques résultats de la radiothérapie et essai de fixation d’une technique rationnelle. Comptes Rendus des Séances de l’Académie des Sciences, 143, 983–985. [Translation: Radiation Research, 11(4), 587–588, 1959.].
- Blanes, S., Casas, F., Oteo, J. A., & Ros, J. (2009). The Magnus expansion and some of its applications. Physics Reports, 470(5–6), 151–238.
- Bortfeld, T., Ramakrishnan, J., Tsitsiklis, J. N., & Unkelbach, J. (2015). Optimization of radiation therapy fractionation schedules in the presence of tumor repopulation. INFORMS Journal on Computing, 27(4), 788–803. [CrossRef]
- Brassesco, M. S., Roberto, G. M., Morales, A. G., et al. (2013). Inhibition of NF-κB by dehydroxymethylepoxyquinomicin suppresses invasion and synergistically potentiates temozolomide and γ-radiation cytotoxicity in glioblastoma cells. Chemotherapy Research and Practice, 2013, 593020. [CrossRef]
- Brenner, D. J. (2008). The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Seminars in Radiation Oncology, 18(4), 234–239. [CrossRef]
- Chis, O.-T., Banga, J. R., & Balsa-Canto, E. (2011). Structural identifiability of systems biology models: A critical comparison of methods. PLoS ONE, 6(11), e27755. [CrossRef]
- Curtis, S. B. (1986). Lethal and potentially lethal lesions induced by radiation — a unified repair model. Radiation Research, 106(2), 252–270. [CrossRef]
- Davern, M., Turner, C. J., Griffin, D., Bencsics, L., Chan, B. C., Kung, J. Y. T.,... & Letai, A. (2025). Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms. Cell Death & Differentiation, 1-18. [CrossRef]
- Davies, P. C. W. (2019). The Demon in the Machine: How Hidden Webs of Information Are Solving the Mystery of Life. University of Chicago Press.
- Dayanc, B., et al. (2025). AP-1 as a targetable mediator of acquired resistance to osimertinib in EGFR-mutant lung cancer. Cell Death & Disease. [CrossRef]
- Di Dio, C., Porrazzo, A., De Gregorio, A., Morciano, P., Tabocchini, M. A., Cenci, G.,... & Esposito, G. (2025). In vivo study of the radioadaptive response and low-dose hyper-radiosensitivity for chromosome breaks induced by gamma rays in wild-type Drosophila melanogaster larval neuroblasts: Dose and dose rate dependence. PLoS One, 20(6), e0325608. [CrossRef]
- Eckert, L., Vidal-Saez, M. S., Zhao, Z., et al. (2024). Habituation as an emergent property of a biochemical feedback network. Current Biology, 34(24), 5646–5658.
- Enderling, H., Chaplain, M. A. J., & Hahnfeldt, P. (2010). Quantitative modeling of tumor dynamics and radiotherapy. Acta Biotheoretica, 58(4), 341–353. [CrossRef]
- Foray, N. (2012). Victor Despeignes (1866–1937): How a hygienist became the first radiation oncologist. Cancer Radiothérapie, 17(3), 244–254. [On the law of Bergonié and Tribondeau.].
- Forissier, V., Rivera-Franco, M. M., Cabeza-Segura, M., et al. (2025). The LRP4/YAP axis drives the radiation-tolerant persister cell state in breast cancer. Theranostics, 15(15), 7528–7546.
- Fowler, J. F. (1989). The linear-quadratic formula and progress in fractionated radiotherapy. British Journal of Radiology, 62(740), 679–694. [CrossRef]
- Fu, A., Kim, H., Chetty, I. J., et al. (2026). Optimal radiotherapy dose scheduling with variable fraction sizes and treatment breaks via sequential convex programming. Physics and Imaging in Radiation Oncology, 39, 101003.
- Gatenby, R. A., & Brown, J. S. (2020). Integrating evolutionary dynamics into cancer therapy. Nature Reviews Clinical Oncology, 17(11), 675–686. [CrossRef]
- Gelman, A., Carlin, J. B., Stern, H. S., et al. (2013). Bayesian Data Analysis (3rd ed.). Chapman and Hall/CRC.
- Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012). Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer, 12(7), 487–493. [CrossRef]
- Gouw, Z. A. R., Jasperse, B., Sonke, J.-J., et al. (2024). Early treatment response assessment during radiotherapy and its use for adaptive fractionation. Radiotherapy and Oncology, 190, 110006.
- Gray, L. H., Conger, A. D., Ebert, M., et al. (1953). The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology, 26(312), 638–648. [CrossRef]
- Gu, J., Mu, N., Jia, B., et al. (2022). Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma. Neuro-Oncology, 24(7), 1056–1070. [CrossRef]
- Gutenkunst, R. N., Waterfall, J. J., Casey, F. P., et al. (2007). Universally sloppy parameter sensitivities in systems biology models. PLoS Computational Biology, 3(10), e189. [CrossRef]
- Hall, E. J., & Giaccia, A. J. (2018). Radiobiology for the Radiologist (8th ed.). Wolters Kluwer.
- Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., McCormick, F., & Bassik, M. C. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature, 551(7679), 247–250. [CrossRef]
- Hawkins, R. B. (1994). A statistical theory of cell killing by radiation of varying linear energy transfer. Radiation Research, 140(3), 366–374. [CrossRef]
- Helbig, L., Koi, L., Brüchner, K., et al. (2014). Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. International Journal of Radiation Oncology, Biology, Physics, 88(1), 159–166. [CrossRef]
- Joiner, M. C., Marples, B., Lambin, P., et al. (2001). Low-dose hypersensitivity: Current status and possible mechanisms. International Journal of Radiation Oncology, Biology, Physics, 49(2), 379–389. [CrossRef]
- Kallman, R. F. (1972). The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology, 105(1), 135–142. [CrossRef]
- Krasowska, J., Kłos, J., Ostrowski, J., & Fornalski, K. W. (2026). Understanding the Radiation Adaptive Response: General Methodology and Theoretical Approaches to the Study of the Radioadaptation Phenomenon. Dose-Response, 24(2), 15593258261442577. [CrossRef]
- Kuznetsov, M., & Kolobov, A. (2023). Optimization of antitumor radiotherapy fractionation via mathematical modeling with account of 4 R’s of radiobiology. Journal of Theoretical Biology, 558, 111371. [CrossRef]
- Levin, M. (2021). Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer. Cell, 184(8), 1971–1989. [CrossRef]
- Lewin, T. D., Maini, P. K., Moros, E. G., Enderling, H., & Byrne, H. M. (2018). The evolution of tumour composition during fractionated radiotherapy: implications for outcome. Bulletin of Mathematical Biology, 80(5), 1207–1235. [CrossRef]
- Li, J., Ravindran, P. T., O’Farrell, A., Busch, G. T., Boe, R. H., Niu, Z.,... & Raj, A. (2026). AP-1 mediates cellular adaptation and memory formation. Nature Communications. [CrossRef]
- Ling, H. H., Huang, H. Y., Huang, C. M., Yasir, M., Ko, C. C., Yadav, V. K.,... & Tsai, J. T. (2026). Drug-tolerant persister cells in head and neck squamous cell carcinoma: Molecular mechanisms and therapeutic opportunities. Translational Oncology, 63, 102579. [CrossRef]
- Magnus, W. (1954). On the exponential solution of differential equations for a linear operator. Communications on Pure and Applied Mathematics, 7(4), 649–673. [CrossRef]
- McMahon, S. J. (2019). The linear quadratic model: Usage, interpretation and challenges. Physics in Medicine & Biology, 64(1), 01TR01. [CrossRef]
- Mothersill, C., & Seymour, C. (2001). Radiation-induced bystander effects: Past history and future directions. Radiation Research, 155(6), 759–767. [CrossRef]
- Ng, E. T. H., & Kinjo, A. R. (2022). Computational modeling of plasticity-led evolution. arXiv:2209.05599. [CrossRef]
- Olivieri, G., Bodycote, J., & Wolff, S. (1984). Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science, 223(4636), 594–597. [CrossRef]
- Pajonk, F., Vlashi, E., & McBride, W. H. (2010). Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited. Stem Cells, 28(4), 639–648. [CrossRef]
- Park, C., Papiez, L., Zhang, S., et al. (2008). Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 70(3), 847–852. [CrossRef]
- Pigozzi, F., Goldstein, A., & Levin, M. (2025). Associative conditioning in gene regulatory network models increases integrative causal emergence. Communications Biology, 8(1), 1027. [CrossRef]
- Powathil, G. G., Adamson, D. J. A., & Chaplain, M. A. J. (2013). Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: Clinical insights from a computational model. PLoS Computational Biology, 9(7), e1003120. [CrossRef]
- Pratx, G., & Kapp, D. S. (2019). A computational model of radiolytic oxygen depletion during FLASH irradiation and its effect on the oxygen enhancement ratio. Physics in Medicine & Biology, 64(18), 185005. [CrossRef]
- Prezado, Y., Grams, M., Jouglar, E., et al. (2024). Spatially fractionated radiation therapy: A critical review on current status of clinical and preclinical studies and knowledge gaps. Physics in Medicine & Biology, 69(10), 10TR02. [CrossRef]
- Raue, A., Kreutz, C., Maiwald, T., et al. (2009). Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics, 25(15), 1923–1929. [CrossRef]
- Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E.,... & Bardelli, A. (2024). Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nature Reviews Cancer, 24(10), 694-717. [CrossRef]
- Scheidegger, S., Fuchs, H. U., Zaugg, K., et al. (2013). Using state variables to model the response of tumour cells to radiation and heat: A novel multi-hit-repair approach. Computational and Mathematical Methods in Medicine, 2013, 587543. [CrossRef]
- Schick, L., Eichenlaub, E., Drexel, F., Mayer, A., Chen, S., Roper, M., & Alim, K. (2026). Decision-making in light-trapped slime molds involves active mechanical processes. PRX Life, 4(2), 023026. [CrossRef]
- Schneider, T., Fernandez-Palomo, C., Bertho, A., et al. (2022). Combining FLASH and spatially fractionated radiation therapy: The best of both worlds. Radiotherapy and Oncology, 175, 169–177. [CrossRef]
- Scott, B. R. (2004). A biological-based model that links genomic instability, bystander effects, and adaptive response. Mutation Research, 568(1), 129–143. [CrossRef]
- Sharma, S. V., Lee, D. Y., Li, B., et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69–80. [CrossRef]
- Sinclair, W. K., & Morton, R. A. (1966). X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiation Research, 29(3), 450–474. [CrossRef]
- Taylor, E. R. J. F., Ruan, J.-L., Paillas, S., Tullis, I. D. C., Higgins, G. S., & Petersson, K. (2026). A preclinical setup for spatially fractionated radiation therapy with electrons. Medical Physics. [CrossRef]
- Vaitheeswaran, R. (2026a). The Ghost in the Cancer: Towards a new science of radiation oncology. Notion Press.
- Vaitheeswaran, R. (2026b). On the observability and structural identifiability of the coupled adaptive-state radiobiology model. Preprints. [CrossRef]
- Vaitheeswaran, R. (2026c). Extending the Kinetic-Bystander Model for Spatially Fractionated Radiotherapy with Intracellular Epigenetic Memory. Preprints. [CrossRef]
- Valcz, G., Gatenby, R. A., Újvári, B., Buzás, E. I., & Molnár, B. (2025). Adaptive cancer therapy: can non-genetic factors become its achilles heel?. Oncogene, 44(42), 3999-4005. [CrossRef]
- Van den Berg, J., Castricum, K. C. M., Meel, M. H., et al. (2020). Development of transient radioresistance during fractionated irradiation in vitro. Radiotherapy and Oncology, 148, 107–114. [CrossRef]
- Vozenin, M.-C., Hendry, J. H., & Limoli, C. L. (2019). Biological benefits of ultra-high dose rate FLASH radiotherapy: Sleeping beauty awoken. Clinical Oncology, 31(7), 407–415. [CrossRef]
- Wang, S., Lei, J., Zou, X., & Jin, S. (2025). Integrating multiscale mathematical modeling and multidimensional data reveals the effects of epigenetic instability on acquired drug resistance in cancer. PLOS Computational Biology, 21(2), e1012815. [CrossRef]
- Wei, J., & Norman, E. (1963). Lie algebraic solution of linear differential equations. Journal of Mathematical Physics, 4(4), 575–581.
- Wolff, S. (1998). The adaptive response in radiobiology: Evolving insights and implications. Environmental Health Perspectives, 106(Suppl 1), 277–283. [CrossRef]
- Yap, T. A., Daver, N., Mahendra, M., Zhang, J., Kamiya-Matsuoka, C., Meric-Bernstam, F., Konopleva, M., et al. (2023). Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature Medicine, 29(1), 115–126. [CrossRef]
- Yu, V. Y., Nguyen, D., Pajonk, F., et al. (2015). Incorporating cancer stem cells in radiation therapy treatment response modeling and the implication in glioblastoma multiforme treatment resistance. International Journal of Radiation Oncology, Biology, Physics, 91(4), 866–875. [CrossRef]
- Zhang, J., Cunningham, J. J., Brown, J. S., & Gatenby, R. A. (2017). Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nature Communications, 8, 1816. [CrossRef]
- Zhao, Y., Li, D., Zhou, Y., et al. (2023). Cancer cells enter an adaptive persistence to survive radiotherapy and repopulate the tumor. Advanced Science, 10(8), 2204177.

| Layer | Var. | Timescale | Biological process | Key references |
|---|---|---|---|---|
| M — redox | x | ms–seconds | radical chemistry; radiolytic oxygen depletion; oxygen enhancement; FLASH oxygen dynamics | Gray et al. 1953; Pratx & Kapp 2019; Vozenin et al. 2019 |
| S — stress signal | s | minutes–hours | DNA-damage and stress signalling; non-targeted (bystander) collective signal | Curtis 1986; Hawkins 1994; Mothersill & Seymour 2001 |
| A — escape gate | a | hours–days | type-I interferon / budding toggle releasing persister progeny | Zhao et al. 2023 |
| B — persister | Np, b | days–weeks | reversible tolerant persister state; write-and-inherit; conserved across tumour types | Gu 2022; Zhao 2023; Forissier 2025; Li 2026 |
| E — population | Ns, Np | weeks–months | clonal evolution under selection; repopulation; adaptive therapy | Gatenby & Brown 2020; Enderling et al. 2010 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).